CN Patent

CN113645975A — 用于治疗尿路上皮癌的fgfr酪氨酸激酶抑制剂

Assigned to Janssen Pharmaceutica NV · Expires 2021-11-12 · 5y expired

What this patent protects

本文描述了用含有成纤维细胞生长因子受体(FGFR)抑制剂的批准的药物产品治疗尿路上皮癌的方法。本文还描述了销售或许诺销售含有成纤维细胞生长因子受体(FGFR)抑制剂的批准的药物产品的方法。

USPTO Abstract

本文描述了用含有成纤维细胞生长因子受体(FGFR)抑制剂的批准的药物产品治疗尿路上皮癌的方法。本文还描述了销售或许诺销售含有成纤维细胞生长因子受体(FGFR)抑制剂的批准的药物产品的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN113645975A
Jurisdiction
CN
Classification
—
Expires
2021-11-12
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Pharmaceutica NV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.